Jazz Pharmaceuticals (JAZZ) Debt to Equity: 2010-2025
Historic Debt to Equity for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $1.35.
- Jazz Pharmaceuticals' Debt to Equity fell 7.58% to $1.35 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.35, marking a year-over-year decrease of 7.58%. This contributed to the annual value of $1.49 for FY2024, which is 2.39% down from last year.
- As of Q3 2025, Jazz Pharmaceuticals' Debt to Equity stood at $1.35, which was down 6.43% from $1.45 recorded in Q2 2025.
- Jazz Pharmaceuticals' 5-year Debt to Equity high stood at $2.09 for Q3 2022, and its period low was $0.55 during Q1 2021.
- Its 3-year average for Debt to Equity is $1.51, with a median of $1.52 in 2024.
- In the last 5 years, Jazz Pharmaceuticals' Debt to Equity spiked by 201.65% in 2022 and then decreased by 21.49% in 2023.
- Over the past 5 years, Jazz Pharmaceuticals' Debt to Equity (Quarterly) stood at $1.53 in 2021, then rose by 21.58% to $1.86 in 2022, then dropped by 17.59% to $1.53 in 2023, then fell by 2.39% to $1.49 in 2024, then dropped by 7.58% to $1.35 in 2025.
- Its Debt to Equity stands at $1.35 for Q3 2025, versus $1.45 for Q2 2025 and $1.29 for Q1 2025.